Form 4: SAB Biotherapeutics Director Jay S. Skyler Receives Stock Option Grants

Director Jay S. Skyler receives stock options as part of annual and inaugural grants for board service.

Summary

• Jay S. Skyler, a director of SAB Biotherapeutics, Inc., received stock option grants on July 15, 2024.
• The grants include an annual grant of 20,000 shares vesting in two equal annual installments starting July 15, 2025, and an inaugural grant of 35,000 shares vesting in three equal annual installments starting May 3, 2025.
• The exercise price for both options is $2.90, and they expire on July 15, 2034.
• The grants were made under the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is neutral in sentiment. It reflects standard compensation practices.

Positives

• The stock option grants align the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment and performance.

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Comparing SAB Biotherapeutics' director compensation to peers like Vir Biotechnology or IGM Biosciences would provide a better understanding of whether the grant size and vesting schedule are competitive.
• Generally, stock option grants vest over a period of 2-4 years, which is consistent with the vesting schedules outlined in this filing.

Stakeholder Impact

• The stock option grants could potentially dilute existing shareholders if the options are exercised.
• The grants incentivize the director to contribute to the long-term success of the company, which benefits shareholders.

Key Dates